A single blind randomised controlled trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of infective exacerbations of Chronic Obstructive Pulmonary Disease
| ISRCTN | ISRCTN13825248 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13825248 |
| Secondary identifying numbers | HTA 03/13/06 |
- Submission date
- 14/03/2005
- Registration date
- 16/03/2005
- Last edited
- 29/10/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Ms Jane Cross
Scientific
Scientific
School of Allied Health Professions
Queens Building
University of East Anglia
Norwich
NR4 7TJ
United Kingdom
| Phone | +44 (0)1603 593315 |
|---|---|
| j.cross@uea.ac.uk |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study acronym | MATREX |
| Study objectives | This study proposes to look exclusively at COPD and compare a group of patients who do receive a chest physiotherapy intervention of manual techniques with a group of patients who receive no manual intervention but are given an information sheet, and to follow up all patients for one year. Please note that, as of 11/05/2009, the anticipated start and end dates have been updated from 01/12/2004 and 31/08/2008 to 01/03/2005 and 30/04/2009, respectively. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Chronic Obstructive Pulmonary Disease (COPD) |
| Intervention | Please note that, as of 10 January 2008, the anticipated start and end dates of this trial have been updated from 1 December 2004 and 31 August 2008 to 1 March 2005 and 30 April 2009, respectively. Interventions: Intervention arm: Participants will receive the respiratory manual techniques of percussion, vibrations and chest shaking. A standard treatment protocol manual will be followed by all the participating hospitals. This manual will be developed with the clinical staff involved in order to represent current practice and optimise compliance. Treatment will be applied with the patient positioned according to an agreed protocol for optimal drainage of secretions. The chest will be percussed whilst the patient performs thoracic expansion exercises and vibrations and shaking will be applied on expiration. Treatment will be interspersed with periods of relaxed abdominal breathing, breathing control. Participants will also be given an information sheet giving advice on positioning, managing cough and mobilisation. The content, number and duration of treatments will be at the discretion of the physiotherapist applying treatment, within the bounds set by the manual and will be varied according to clinical need. This information will be recorded. Oxygen saturation will be monitored and recorded during treatment. Once the patient has returned to his/her normal stable saturation, monitoring will stop. Sputum produced in each 24 hour period will be collected and its volume measured throughout each hospital admission. Control arm: Participants will receive no manual chest physiotherapy. They will be given the same information sheet giving advice on positioning, managing coughing and mobilisation by a physiotherapist. 24 hour sputum volumes will be measured as for the intervention group. For patients in the control arm who show severe deterioration due to sputum retention, additional physiotherapy including manual techniques will be permitted. Such movement between trial arms will be monitored closely. Movement between arms will occur where there is clear clinical evidence of sputum retention (Auscultation/chest x-ray [CXR] evidence) in conjunction with a pH of less than 7.26, a rising CO2 in patients already receiving supportive treatment and controlled oxygen therapy. The primary analysis will be intention to treat. A per protocol analysis will be performed as a secondary analysis, with adjustment for baseline differences. |
| Intervention type | Other |
| Primary outcome measure | Quality of Life (St Georges Respiratory Questionnaire) at baseline, six weeks, three months, six months and one year post intervention. |
| Secondary outcome measures | Quality of life, breathlessness and exercise tolerance: 1. Breathlessness, Cough and Sputum Scale (QOL) 2. EuroQol five dimensional instrument (EQ-5D) 3. Sputum volume and oxygen saturation during hospitalisation 4. Total number of days spent in hospital during 12 months period 5. Marginal cost-utility ratio for manual versus no manual chest physiotherapy |
| Overall study start date | 01/03/2005 |
| Completion date | 30/04/2009 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 550 |
| Key inclusion criteria | Patients admitted to participating hospitals with infective exacerbations of COPD. Inclusion Criteria: 1. Diagnosis of COPD as defined by the British Thoracic Society; namely a. A forced expiratory volume in the first second (FEV1) of <80% of the predicted value, which is predominantly irreversible b. Signs and symptoms of cough, breathlessness and +/- wheeze c. In more severe disease there may be cyanosis and peripheral oedema 2. An infective exacerbation as set out by the British Thoracic Society; namely a. A worsening of previous stable condition, a new respiratory event or complication imposed upon established COPD b. Signs and symptoms of increased wheeze, dyspnoea, sputum volume and purulence, chest tightness and fluid retention |
| Key exclusion criteria | 1. Cognitive impairment, rendering patients unable to give fully informed consent 2. Contraindications to the use of manual techniques; namely a. Osteoporosis b. Frank haemoptysis c. Bronchial hyper-reactivity d. Known respiratory system malignancy 3. No evidence of excess sputum production after examination (i.e. the patient does not report excess secretions and no signs of excess secretions on auscultation) |
| Date of first enrolment | 01/03/2005 |
| Date of final enrolment | 30/04/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
School of Allied Health Professions
Norwich
NR4 7TJ
United Kingdom
NR4 7TJ
United Kingdom
Sponsor information
University of East Anglia (UK)
University/education
University/education
-
Norwich
NR4 7TJ
England
United Kingdom
| Website | http://www1.uea.ac.uk/cm/home |
|---|---|
"ROR" |
https://ror.org/026k5mg93 |
Funders
Funder type
Government
NIHR Health Technology Assessment Programme - HTA (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/05/2010 | Yes | No | |
| Results article | results | 02/07/2012 | Yes | No |
